News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
302,112 Results
Type
Article (15060)
Company Profile (283)
Press Release (286769)
Section
Business (94447)
Career Advice (188)
Deals (14865)
Drug Delivery (35)
Drug Development (51435)
Employer Resources (32)
FDA (6074)
Job Trends (5708)
News (161577)
Policy (10533)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (992)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (22729)
ALS (61)
Alzheimer's disease (846)
Antibody-drug conjugate (ADC) (89)
Approvals (6095)
Artificial intelligence (125)
Autoimmune disease (13)
Automation (5)
Bankruptcy (111)
Best Places to Work (5102)
BIOSECURE Act (5)
Biosimilars (40)
Biotechnology (234)
Bladder cancer (45)
Brain cancer (20)
Breast cancer (149)
Cancer (1339)
Cardiovascular disease (115)
Career advice (164)
Career pathing (2)
CAR-T (108)
Cell therapy (312)
Cervical cancer (8)
Clinical research (41777)
Collaboration (518)
Compensation (228)
Complete response letters (13)
COVID-19 (1061)
CRISPR (37)
C-suite (147)
Cystic fibrosis (77)
Data (1409)
Denatured (11)
Depression (30)
Diabetes (132)
Diagnostics (1707)
Digital health (5)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (79)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (83)
Earnings (42428)
Editorial (19)
Employer branding (4)
Employer resources (30)
Events (60207)
Executive appointments (412)
FDA (6730)
Featured Employer (31)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (481)
Gene editing (93)
Generative AI (9)
Gene therapy (237)
GLP-1 (372)
Government (1113)
Grass and pollen (2)
Guidances (24)
Healthcare (7537)
Huntington's disease (21)
IgA nephropathy (22)
Immunology and inflammation (81)
Indications (18)
Infectious disease (1124)
Inflammatory bowel disease (115)
Inflation Reduction Act (8)
Influenza (20)
Intellectual property (59)
Interviews (19)
IPO (8467)
IRA (11)
Job creations (920)
Job search strategy (156)
Kidney cancer (6)
Labor market (4)
Layoffs (206)
Leadership (3)
Legal (1455)
Liver cancer (31)
Lung cancer (189)
Lymphoma (84)
Machine learning (1)
Management (7)
Manufacturing (118)
MASH (49)
Medical device (3937)
Medtech (3939)
Mergers & acquisitions (6705)
Metabolic disorders (374)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (62)
Neuropsychiatric disorders (23)
Neuroscience (1228)
NextGen: Class of 2025 (2289)
Non-profit (914)
Northern California (1734)
Now hiring (21)
Obesity (190)
Opinion (101)
Ovarian cancer (60)
Pain (43)
Pancreatic cancer (51)
Parkinson's disease (111)
Partnered (8)
Patents (112)
Patient recruitment (69)
Peanut (35)
People (26432)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14620)
Phase II (19413)
Phase III (12382)
Pipeline (782)
Podcasts (47)
Policy (39)
Postmarket research (907)
Preclinical (6120)
Press Release (30)
Prostate cancer (56)
Psychedelics (35)
Radiopharmaceuticals (215)
Rare diseases (281)
Real estate (1654)
Recruiting (13)
Regulatory (8997)
Reports (16)
Research institute (995)
Resumes & cover letters (23)
Rett syndrome (4)
RNA editing (4)
RSV (11)
Schizophrenia (57)
Series A (94)
Series B (61)
Service/supplier (1)
Sickle cell disease (40)
Southern California (1525)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (2060)
State (1)
Stomach cancer (5)
Supply chain (18)
Tariffs (3)
The Weekly (35)
United States (13471)
Vaccines (208)
Venture capitalists (29)
Webinars (7)
Weight loss (109)
Women's health (15)
Worklife (2)
Date
Today (39)
Last 7 days (430)
Last 30 days (1643)
Last 365 days (21466)
2025 (5367)
2024 (22227)
2023 (24645)
2022 (29472)
2021 (30727)
2020 (26073)
2019 (18435)
2018 (13276)
2017 (15033)
2016 (13198)
2015 (16383)
2014 (11822)
2013 (8532)
2012 (8836)
2011 (9138)
2010 (8739)
Location
Africa (176)
Alabama (38)
Alaska (2)
Arizona (58)
Arkansas (5)
Asia (18207)
Australia (3027)
California (3915)
Canada (1144)
China (333)
Colorado (148)
Connecticut (164)
Delaware (89)
Europe (39466)
Florida (482)
Georgia (125)
Idaho (18)
Illinois (235)
India (9)
Indiana (110)
Iowa (2)
Japan (73)
Kansas (61)
Kentucky (6)
Louisiana (3)
Maine (23)
Maryland (480)
Massachusetts (3074)
Michigan (75)
Minnesota (171)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (15)
New Hampshire (15)
New Jersey (965)
New Mexico (13)
New York (1037)
North Carolina (570)
North Dakota (5)
Northern California (1734)
Ohio (114)
Oklahoma (9)
Oregon (21)
Pennsylvania (758)
Puerto Rico (3)
Rhode Island (18)
South America (249)
South Carolina (5)
Southern California (1525)
Tennessee (27)
Texas (449)
Utah (69)
Virginia (71)
Washington D.C. (30)
Washington State (357)
West Virginia (1)
Wisconsin (18)
302,112 Results for "arch therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Venture capital
ARCH Fuels Up With $3B to Support Next Class of AI Biotechs
ARCH Venture Partners is the latest venture capital firm to raise a multi-billion-dollar fund. The cash will be used to support new startups working with AI.
September 26, 2024
·
1 min read
·
Annalee Armstrong
Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product
Arch Biopartners Inc. announced that Dalton Pharma Services (Dalton) has completed the good manufacturing practice (GMP) glass vial filling stage for cilastatin, the Company’s second drug candidate for preventing acute kidney injury (AKI).
June 27, 2024
·
5 min read
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive two-year topline results from the ARCH trial. ARCH is an open label, single-center study assessing safety, tolerability, impact on muscle damage biomarkers, pharmacokinetics (PK) and functional measures with sevasemten (EDG-5506) in adults with Becker.
April 15, 2024
·
12 min read
Press Releases
Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI)
February 18, 2025
·
6 min read
Press Releases
Arch Biopartners Arranges Non-Brokered Private Placement
October 15, 2024
·
3 min read
Genetown
Arch Therapeutics Provides Year End Operational Update
Arch Therapeutics, Inc., a marketer and developer of novel self-assembling wound care and biosurgical products, provided a year-end operational update, including key performance metrics related to the ongoing commercialization activities for the Company’s first product, AC5® Advanced Wound System.
November 9, 2023
·
6 min read
Business
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)
October 1, 2024
·
5 min read
Genetown
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring) A Study of AC5® Advanced Wound System in Patients with Lower Extremity Wounds to be Featured in a Clinical Poster
Arch Therapeutics, Inc. announced that the Company’s first commercial product, AC5® Advanced Wound System, will be featured at the 2024 Symposium on Advanced Wound Care Spring Meeting, which takes place at Orlando Marriott World Center, Orlando, from May 14-18, 2024.
May 6, 2024
·
5 min read
Venture capitalists
Blackstone Launches New $5B+ Fund for Life Sciences
Blackstone joins other big investors such as ARCH Venture Partners and Bain Capital Life Sciences in pumping billions of dollars into the industry.
January 31, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)
January 9, 2025
·
6 min read
1 of 30,212
Next